Smith Benjamin, Goldstein Todd, Ekstein Charles
Department of Orthopedic Surgery and Orthopedic Research Laboratory, Feinstein Institute for Medical Research and North Shore-LIJ Health System, Manhasset, NY, USA,
Curr Rev Musculoskelet Med. 2015 Jun;8(2):193-9. doi: 10.1007/s12178-015-9265-z.
Normal bone healing is a complex process that eventually restores original structure and function to the site of trauma. However, clinical circumstances such as nonunion, critical-sized defects, systemic bone disease, and fusion procedures have stimulated a search for ways to enhance this normal healing process. Biologics are an important part of this search and many, including bone marrow aspirate concentrate, demineralized bone matrix, platelet-rich plasma, bone morphogenic proteins, and platelet-derived growth factor, are currently in clinical use. Many others, including mesenchymal stem cells, parathyroid hormone, and Nel-like molecule-1 (NELL-1) will likely be in use in the future depending on the results of preclinical and clinical trials.
正常的骨愈合是一个复杂的过程，最终能使创伤部位恢复原始结构和功能。然而，诸如骨不连、临界尺寸缺损、全身性骨病以及融合手术等临床情况，促使人们探寻增强这种正常愈合过程的方法。生物制剂是这一探寻的重要组成部分，许多生物制剂，包括骨髓抽吸浓缩物、脱矿骨基质、富血小板血浆、骨形态发生蛋白以及血小板衍生生长因子，目前都在临床中使用。其他许多制剂，包括间充质干细胞、甲状旁腺激素以及尼尔样分子1（NELL-1），根据临床前和临床试验的结果，未来可能也会投入使用。
